Cargando…
ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score
Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) are chronic liver disorders, the prevalence of which is increasing worldwide. Long term High Fat Diet (HFD) induced NASH animal models closely mimic the characteristics of human NASH and hence used by investigators as...
Autores principales: | Sanjay, K.V., Vishwakarma, Santosh, Zope, Bharat Ravindra, Mane, Vishal Subhash, Mohire, Sunil, Dhakshinamoorthy, Saravanakumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663992/ https://www.ncbi.nlm.nih.gov/pubmed/34909677 http://dx.doi.org/10.1016/j.crphar.2021.100051 |
Ejemplares similares
-
Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
por: Bilen, Ozlem, et al.
Publicado: (2016) -
Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
por: Pinkosky, Stephen L., et al.
Publicado: (2016) -
Allosteric role of the citrate synthase homology domain of ATP citrate lyase
por: Wei, Xuepeng, et al.
Publicado: (2023) -
Improving the Assessment of Neonatal Abstinence Syndrome (NAS)
por: Chin Foo, Claire A., et al.
Publicado: (2021) -
Exploring the Role of ATP-Citrate Lyase in the Immune System
por: Dominguez, Monica, et al.
Publicado: (2021)